Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation
- PMID: 8637703
Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation
Abstract
The c-ret proto-oncogene with multiple endocrine neoplasia (MEN) 2A or 2B mutation can transform NIH3T3 cells with high efficiencies as a consequence of its constitutive activation. The MEN2A mutation induces ligand-independent homodimerization of the Ret protein on the cell surface while the MEN2B mutation appears to alter the catalytic activity without dimerization. In the present study, we investigated the role of tyrosine residues present in the kinase domain for the transforming activity of the mutant Ret proteins. Substitution of phenylalanine for tyrosine 905 (Y905F) that corresponds to tyrosine 416 of the Src protein abolished the transforming activity of Ret with the MEN2A mutation (MEN2A-Ret) but not with the MEN2B mutation (MEN2B-Ret). On the other hand, the transforming activity of MEN2B-Ret but not MEN2A-Ret significantly decreased by changing tyrosine 864 or 952 to phenylalanine. In addition, double mutations of these tyrosines (Y864/952F) completely abolished the activity of MEN2B-Ret. The Y905F and Y864/952F mutations resulted in severe impairment of the kinase activity of MEN2A-Ret and MEN2B-Ret, respectively. These results thus indicated that tyrosine residues essential for the transforming activity are different between MEN2A-Ret and MEN2B-Ret.
Similar articles
-
Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.Cancer Res. 2001 Feb 15;61(4):1426-31. Cancer Res. 2001. PMID: 11245446
-
A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins.J Biol Chem. 1996 Jul 26;271(30):17644-9. doi: 10.1074/jbc.271.30.17644. J Biol Chem. 1996. PMID: 8663426
-
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.Science. 1995 Jan 20;267(5196):381-3. doi: 10.1126/science.7824936. Science. 1995. PMID: 7824936
-
Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations.Recent Results Cancer Res. 1998;154:229-36. doi: 10.1007/978-3-642-46870-4_14. Recent Results Cancer Res. 1998. PMID: 10027003 Review.
-
Molecular mechanism of activation and superactivation of Ret tyrosine kinases by ultraviolet light irradiation.Antioxid Redox Signal. 2000 Winter;2(4):841-9. doi: 10.1089/ars.2000.2.4-841. Antioxid Redox Signal. 2000. PMID: 11213488 Review.
Cited by
-
Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.J Pers Med. 2023 Jul 13;13(7):1132. doi: 10.3390/jpm13071132. J Pers Med. 2023. PMID: 37511745 Free PMC article. Review.
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
-
Peptides containing the MXXCW motif inhibit oncogenic RET kinase activity with a novel mechanism of action.Am J Cancer Res. 2020 Jan 1;10(1):336-349. eCollection 2020. Am J Cancer Res. 2020. PMID: 32064171 Free PMC article.
-
PTPRA Phosphatase Regulates GDNF-Dependent RET Signaling and Inhibits the RET Mutant MEN2A Oncogenic Potential.iScience. 2020 Feb 21;23(2):100871. doi: 10.1016/j.isci.2020.100871. Epub 2020 Jan 31. iScience. 2020. PMID: 32062451 Free PMC article.
-
Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.Int J Oncol. 2017 Jul;51(1):145-157. doi: 10.3892/ijo.2017.3994. Epub 2017 May 11. Int J Oncol. 2017. PMID: 28498409 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Molecular Biology Databases
Miscellaneous